Patient Prefer Adherence. 2012;6:369-88. Epub 2012 May 1.

Treatment-resistant depression: therapeutic trends, challenges, and future directions.

Al-Harbi KS.

Source

Medical College, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.

Abstract

BACKGROUND:

Patients with major depression respond to antidepressant treatment, but 10%-30% of them do not improve or show a partial response coupled with functional impairment, poor quality of life, suicide ideation and attempts, self-injurious behavior, and a high relapse rate. The aim of this paper is to review the therapeutic options for treating resistant major depressive disorder, as well as evaluating further therapeutic options.

METHODS:

In addition to Google Scholar and Quertle searches, a PubMed search using key words was conducted, and relevant articles published in English peer-reviewed journals (1990-2011) were retrieved. Only those papers that directly addressed treatment options for treatment-resistant depression were retained for extensive review.

RESULTS:

Treatment-resistant depression, a complex clinical problem caused by multiple risk factors, is targeted by integrated therapeutic strategies, which include optimization of medications, a combination of antidepressants, switching of antidepressants, and augmentation with non-antidepressants, psychosocial and cultural therapies, and somatic therapies including electroconvulsive therapy, repetitive transcranial magnetic stimulation, magnetic seizure therapy, deep brain stimulation, transcranial direct current stimulation, and vagus nerve stimulation. As a corollary, more than a third of patients with treatment-resistant depression tend to achieve remission and the rest continue to suffer from residual symptoms. The latter group of patients needs further study to identify the most effective therapeutic modalities. Newer biomarker-based antidepressants and other drugs, together with non-drug strategies, are on the horizon to address further the multiple complex issues of treatment-resistant depression.

CONCLUSION:

Treatment-resistant depression continues to challenge mental health care providers, and further relevant research involving newer drugs is warranted to improve the quality of life of patients with the disorder.

PMID:

22654508

[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/22654508

Related citations in PubMed

• Review Therapeutic options for treatment-resistant depression.[CNS Drugs. 2010]
  Review Therapeutic options for treatment-resistant depression.

  Shelton RC, Osuntokun O, Heinloth AN, Corya SA. CNS Drugs. 2010 Feb; 24(2):131-61.
• Review Treatment resistant depression--advances in somatic therapies.[Ann Clin Psychiatry. 2007]
  Review Treatment resistant depression--advances in somatic therapies.

  Kennedy SH, Giacobbe P. Ann Clin Psychiatry. 2007 Oct-Dec; 19(4):279-87.
• Review Treatment-resistant depression: no panacea, many uncertainties. Adverse effects are a major factor in treatment choice.[Prescrire Int. 2011]
  Review Treatment-resistant depression: no panacea, many uncertainties. Adverse effects are a major factor in treatment choice.

  . Prescrire Int. 2011 May; 20(116):128-33.
• Review Treatment-resistant depression: new therapies on the horizon.[Ann Clin Psychiatry. 2003]
  Review Treatment-resistant depression: new therapies on the horizon.

  Trivedi MH. Ann Clin Psychiatry. 2003 Mar; 15(1):59-70.
• No health without mental health: A role for the cochrane collaboration.[Cochrane Database Syst Rev. 2010]